Winstrol 50 mg 50 Tablets Nakon Medical USA

Product Overview

Nakon Medical USA’s Winstrol 50 mg presents stanozolol, featuring C2-C3 pyrazole substitution preventing aromatization characteristic of 17α-methylated DHT derivatives (~8-hour half-life), in USP-equivalent scored tablets for institutional catalogs. The 50-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring batch traceability essential for DEA-regulated workflows.

U.S. domestic manufacturing eliminates customs exposure distinguishing legitimate Schedule III supply from underground tablet presses prevalent in non-verified markets. High-dosage format serves advanced resellers managing controlled substance inventories rather than discontinued prescription Winstrol (2 mg).​

Brand & Manufacturer Information

Nakon Medical USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. Winstrol 50 mg maintains catalog continuity alongside Nakon Primo authenticating legitimate institutional supply versus powder-converted alternatives.​

Active Compound Information

Contains stanozolol (17α-methyl-2’H-5α-androst-2-enopyrazol-17β-ol), heterocyclic DHT derivative enabling high anabolic:androgenic dissociation with no estrogen conversion and moderate hepatotoxicity profile characteristic of 17α-methylated oral steroids. DEA Schedule III (21 CFR 1308.13) reflects performance dosage escalation potential.​

Product Specifications

Legal & Regulatory Disclaimer

Stanozolol constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.